Intercure (INCR) AI Stock Analysis

• Market Cap: 280.47M
• Dividend Yield: N/A
• Average Volume (3M): 62.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IL
• Employees: 320
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 54,512,608
• 10 Day Avg. Volume: 41,096
• 30 Day Avg. Volume: 62,757
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: 548.42
• Price Target Upside: 6.59% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 52 Neutral
• Price Target: 548.00 ▲(6.51% Upside)

Intercure's overall stock score is primarily impacted by its financial performance challenges, including declining revenues and negative profitability. Technical analysis provides a neutral outlook with some potential for upward movement. Valuation remains uncertain due to a lack of data, adding to the overall risk profile.

Intercure Business Overview & Revenue Model

Company Description

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

How the Company Makes Money

Intercure generates revenue through multiple streams, primarily from the sale of medical cannabis products to patients and healthcare providers. The company's revenue model is bolstered by direct sales through its dispensaries and online platforms, facilitating access for patients in need of medical cannabis. Additionally, Intercure benefits from partnerships with healthcare institutions and other stakeholders in the medical community, enhancing its market presence and credibility. The company may also explore opportunities for licensing its products or technologies, further diversifying its income sources. Key factors contributing to its earnings include regulatory approvals for its product lines, the expansion of its distribution network, and increasing consumer demand for medical cannabis alternatives.

Intercure Financial Statement Overview

Summary

Intercure is facing financial challenges with declining revenues, negative profitability, and cash flow issues. While the balance sheet shows manageable leverage, the decreasing equity and cash flow difficulties could hinder future growth and stability.

Income Statement

Intercure has experienced a significant decline in revenue and profitability over the reported periods. The gross profit margin decreased, and the company reported negative EBIT and EBITDA margins, indicating operational challenges. Net profit margin is also negative, reflecting ongoing losses.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio, showing some leverage but not excessively high. However, the stockholders' equity has been decreasing, which could be concerning. The equity ratio suggests a fair level of equity financing, but declining equity may pose future risks.

Cash Flow

Intercure's cash flow statement highlights negative free cash flow and operating cash flow, indicating cash flow difficulties. The company also struggles with generating positive cash flow relative to net income, suggesting inefficiencies in cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	238.84M	355.55M	388.68M	219.68M	65.03M
Gross Profit	30.23M	105.09M	155.08M	91.13M	31.98M
EBITDA	-51.31M	-23.90M	70.23M	31.17M	-34.53M
Net Income	-67.80M	-61.96M	44.82M	4.69M	-37.23M
Balance Sheet
Total Assets	762.57M	786.61M	958.01M	686.32M	326.27M
Cash, Cash Equivalents and Short-Term Investments	78.65M	101.33M	232.79M	196.55M	38.26M
Total Debt	211.40M	195.68M	255.16M	108.91M	6.68M
Total Liabilities	364.90M	329.55M	436.53M	227.13M	34.16M
Stockholders Equity	396.97M	455.11M	501.31M	448.03M	274.51M
Cash Flow
Free Cash Flow	-71.30M	-56.25M	31.52M	10.99M	-13.04M
Operating Cash Flow	-66.93M	-53.63M	51.27M	25.02M	7.80M
Investing Cash Flow	17.69M	4.77M	-142.50M	-65.21M	-22.76M
Financing Cash Flow	26.45M	-82.89M	120.45M	203.06M	25.29M

Intercure Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 514.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:INCR, the sentiment is Negative. The current price of 514.5 is below the 20-day moving average (MA) of 541.07, below the 50-day MA of 531.55, and below the 200-day MA of 552.76, indicating a bearish trend. The MACD of -5.07 indicates Positive momentum. The RSI at 40.16 is Neutral, neither overbought nor oversold. The STOCH value of 29.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:INCR.

Intercure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INCR	52 Neutral	280.47M	―		―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%